TY - JOUR
KW - biphasic insulin aspart 30
KW - glucagon-like peptide-1 receptor agonist
KW - Type 2 diabetes
AU - M. Davies
AU - A. Alibegovic
AU - G. Anil
AU - U. Braae
AU - A. Jensen
AU - R. Nordsborg
AD - Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester General Hospital, Leicester, UK.
NIHR Leicester Biomedical Research Centre, Leicester General Hospital, Leicester, UK.
Medical and Science, Diabetes, Novo Nordisk A/S, Søborg, Denmark.
Global Medical Affairs, Novo Nordisk Service Centre India Private Ltd, Bangalore, India.
Real-World Science, Novo Nordisk A/S, Søborg, Denmark.
AN - 38088483
BT - Diabet Med
DO - 10.1111/dme.15267
DP - NLM
ET - 2023/12/13
LA - eng
N1 - 1464-5491
Davies, Melanie
Orcid: 0000-0002-9987-9371
Alibegovic, Amra Ciric
Anil, Gayathri
Braae, Uffe Christian
Jensen, Anders Boeck
Nordsborg, Rikke Baastrup
Novo Nordisk/
Journal Article
England
Diabet Med. 2023 Dec 13:e15267. doi: 10.1111/dme.15267.
PY - 2023
SN - 0742-3071
EP - e15267
T2 - Diabet Med
TI - Real-world study of the concomitant use of biphasic insulin as part 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes
ER -